24764-97-4

Usage

Uses

Used in Pharmaceutical Industry:
2-bromo-butyraldehyde is used as a key intermediate for the synthesis of various pharmaceuticals, contributing to the development of new drugs and improving the efficacy of existing medications.
Used in Pesticide Industry:
2-bromo-butyraldehyde is used as a precursor in the production of pesticides, helping to create effective and safer agrochemicals for agricultural applications.
Used in Fine Chemicals Industry:
2-bromo-butyraldehyde is used as an intermediate in the synthesis of other fine chemicals, playing a crucial role in the production of specialty chemicals for various applications.
Used in Fragrance and Flavoring Industry:
2-bromo-butyraldehyde is used as a building block in the synthesis of fragrances and flavoring compounds, enhancing the variety and quality of scents and tastes in consumer products.
Used in Plastics Industry:
2-bromo-butyraldehyde is used in the manufacturing of plastics, contributing to the development of new plastic materials with improved properties.
Used in Dyes Industry:
2-bromo-butyraldehyde is used in the production of dyes, playing a role in creating a wide range of colorants for various applications.
Used in Rubber Chemicals Industry:
2-bromo-butyraldehyde is used in the manufacturing of rubber chemicals, aiding in the development of rubber products with enhanced performance characteristics.

Upstream product

• 4461-87-4 1,1-dimethoxybutane 
• 123-72-8 butyraldehyde 
• 71-36-3 butan-1-ol 
• 14548-12-0 1-Dimethylamino-1-buten 
• 21947-77-3 cis-2-chloro-3-ethyl-oxirane 
• 39583-28-3 2-ethyl-3-nitro-oxirane 
• 61759-12-4 2-phenylselanylbutanal 
• 67-66-3 chloroform 
• 7726-95-6 bromine 
• 60-29-7 diethyl ether 
• 56249-61-7 N-butylidenebenzylamine 
• 71-43-2 benzene 
• 7707-71-3 butylidene-propyl-amine 
• 4275-07-4 N-butylideneaniline 

Downstream Products

• 19961-52-5 5-ethyl-2-methylthiazole 
• 7422-95-9 1-dimethylamino-1-aza-1,3-pentadiene 
• 15729-76-7 2,5-diethylthiazole 
• 80387-13-9 2-(benzoyloxy)butanal 
• 64689-43-6 (Z)-4-Bromo-1-(4-fluoro-phenyl)-hex-2-en-1-one 
• 39136-60-2 5-ethylthiazol-2-amine 
• 130570-57-9 4-benzyloxy-2,3-dimethyl-7-methoxyindole 
• 10045-49-5 5-ethyl-2-phenylthiazole 
• 901304-49-2 C₂₀H₂₃N₃OS 
• 35874-97-6 α-(phenylthio)butanal 
• 17626-73-2 5-ethylthiazole 
• 92722-12-8 4-amino-N-(5-ethyl-oxazol-2-yl)-benzenesulfonamide 
• 7472-25-5 1,1-dimethoxy-butan-2-ol 

Relevant academic research and scientific papers

Catalytic Diastereoselective Hetero-Diels-Alder Reaction of α-Haloacroleins with Alkenes: Construction of 3,4-Dihydropyran

In this Letter, a catalytic diastereoselective hetero-Diels-Alder reaction of α-haloacroleins with less polarized alkenes was developed, and the resulting 3,4-dihydropyrans were produced in high yields with a broad substate scope. Mechanism studies showed that 3,4-dihydropyran was produced from the ring expansion of cyclobutane, which was generated in the ring contraction of the initially formed unstable 3,4-dihydropyran conformer.

Rational design of photochromic diarylbenzene with both high photoreactivity and fast thermal back reactivity

Recently, diarylbenzenes (DABs) have been developed as a new family of T-type photochromic molecules. In this work, we newly designed and synthesized DABs for the creation of molecules with both high photoreactivity and fast thermal back reactivity. Utilizing the intramolecular CH-N hydrogen bonding and the bulky substituents at the reactive carbons resulted in the enhancement of photoreactivity and the acceleration of the thermal back reaction rate. Furthermore, we demonstrated that the high photoreactivity resulted in much better coloration compared with that of the previously reported DAB even at a lower concentration. These results would not only provide a strategy for molecular design but also be useful for the development of materials with less environmental load.

MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS

Inhibitors of HCV replication of formula (I) and the N-oxides, salts, or stereoisomers thereof, wherein each dashed line (represented by ------) represents an optional double bond; X is N, CH and where X bears a double bond it is C; R1 is -OR6, -NH-SO2R7; R2 is hydrogen, and where X is C or CH, R2 may also be C1-6alkyl; R3 is hydrogen, C1-6alkyl, C1-6alkoxyC1-6alkyl, or C3-7cycloalkyl; n is 3, 4, 5, or 6; R4 and R5 independently from one another are hydrogen, halo, hydroxy, nitro, cyano, carboxyl, C1-6alkyl, C1-6alkoxy, C1-6alkoxyC1-6alkyl, C1-6alkylcarbonyl, C1-6alkoxy- carbonyl, amino, azido, mercapto, C1-6alkylthio, polyhaloC1-6alkyl, aryl or Het; W is aryl or Het; R6 is hydrogen; aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; R7 is aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; aryl is phenyl or naphthyl, each optionally substituted with 1-3 substituents; Het is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1 - 4 heteroatoms each independently selected from N, O or S, and optionally substituted with 1 -3 substituents; pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I). Bioavailable combinations of the inhibitors of HCV of formula (I) with ritonavir are also provided.

Discovery and SAR of 2-aminothiazole inhibitors of cyclin-dependent kinase 5/p25 as a potential treatment for Alzheimer's disease

High-throughput screening with cyclin-dependent kinase 5 (cdk5)/p25 led to the discovery of N-(5-isopropyl-thiazol-2-yl)isobutyramide (1). This compound is an equipotent inhibitor of cdk5 and cyclin-dependent kinase 2 (cdk2)/cyclin E (IC50 = ca. 320 nM). Parallel and directed synthesis techniques were utilized to explore the SAR of this series. Up to 60-fold improvements in potency at cdk5 and 12-fold selectivity over cdk2 were achieved.

Thiazole derivatives

The invention provides compounds of formula 1 wherein R1, R3, and R4 are as defined, and their pharmaceutically acceptable salts. Compounds of formula 1 are indicated to have activity inhibiting cdk5, cdk2, and GSK-3. Pharmaceutical compositions and methods comprising compounds of formula 1 for treating diseases and conditions comprising abnormal cell growth, such as cancer, and neurodegenerative diseases and conditions and those affected by dopamine neurotransmission are described. Also described are pharmaceutical compositions and methods comprising compounds of formula 1 for treating male fertility and sperm motility; diabetes mellitus; impaired glucose tolerance; metabolic syndrome or syndrome X; polycystic ovary syndrome; adipogenesis and obesity; myogenesis and frailty, for example age-related decline in physical performance; acute sarcopenia, for example muscle atrophy and/or cachexia associated with burns, bed rest, limb immobilization, or major thoracic, abdominal, and/or orthopedic surgery; sepsis; hair loss, hair thinning, and balding; and immunodeficiency.

Thiazole derivatives and their use as cdk inhibitors

The invention provides compounds of formula 1 wherein R1, R3, and R4 are as defined, and their pharmaceutically acceptable salts. Compounds of formula 1 are indicated to have activity inhibiting cdk5, cdk2, and GSK-3. Pharmaceutical compositions and methods comprising compounds of formula 1 for treating diseases and conditions comprising abnormal cell growth, such as cancer, and neurodegenerative diseases and conditions and those affected by dopamine neurotransmission are described. Also described are pharmaceutical compositions and methods comprising compounds of formula 1 for treating male fertility and sperm motility; diabetes mellitus; impaired glucose tolerance; metabolic syndrome or syndrome X; polycystic ovary syndrome; adipogenesis and obesity; myogenesis and frailty, for example age-related decline in physical performance; acute sarcopenia, for example muscle atrophy and/or cachexia associated with burns, bed rest, limb immobilization, or major thoracic, abdominal, and/or orthopedic surgery; sepsis; hair loss, hair thinning, and balding; and immunodeficiency.

Studies in selectivity aspects in the synthesis of aliphatic α-bromoaldehydes

A highly selective process scheme was developed to synthesize α-bromoaldehydes by regulating the important process parameters from a reaction-engineering point of view. Thus, α-bromobutyraldehyde and α-bromoheptaldehyde were synthesized in very high selec

THE MUKAIYAMA REACTION OF KETENE BIS(TRIMETHYLSILYL)ACETALS WITH α-HALO ACETALS - A CONVENIENT BUTENOLIDE SYNTHESIS

Ketene bis(trimethylsilyl) acetals were reacted with α-halo acetals giving β-alkoxy-γ-halo acids which were converted to butenolides by reaction with equivalents of base.This constitutes a novel and short butenolide synthesis.

REACTIVITY OF α-ARYLSELENO-ALDEHYDES TOWARDS HALOGENS AND BENZENESELENENYL CHLORIDE

Chlorination of α-seleno-aldehydes bearing an α-hydrogen gives selenium dichlorides which decompose into α-chloro α-seleno-aldehydes and α-chloroenal.Bromination, in all cases, and chlorination for the other α-seleno-aldehydes lead to the α-halogenoaldehydes.